Perioperative medicine & outcomes

Opioid-free anesthesia for minimally invasive abdominal surgery: a systematic review, meta-analysis, and trial sequential analysis

Can J AnaesthPublished Systematic review and meta-analysis of randomised trials

Pooled result · PONV and bradycardiaResult — go to the resultRelative risk 0.55 95% CI 0.40–0.74

Authors' conclusion

Opioid-free anesthesia showed a significant reduction in PONV and a decrease in opioid consumption during the first 2 hr postoperatively

Study context

Population
Patients undergoing minimally invasive abdominal surgery
Participants
2,025 patients · 26 randomized controlled trials (RCTs)
Comparison
Opioid-free vs opioid anesthesia
  • Opioid-free anesthesian = 1,009
Outcome
Adverse effects (PONV, bradycardia)
Methodological detailstrial sequential analysis
  • Trial sequential analysis

Pooled result

PONV and bradycardia

Relative risk

0.55

95% CI 0.40–0.74

P < 0.001

Opioid-free anesthesia vs Opioid anesthesia
RR 0.55 (95% CI 0.40–0.74); P < 0.001

As reported in the abstract

Further pooled results

OutcomeMD (95% CI)P value
Pain scores−0.9 (−1.7 to −0.2)P = 0.01
OutcomeMD (mg oral morphine equivalents) (95% CI)P value
Opioid consumption · 2 hr post surgeryNonclinically relevant−5.4 (−9.1 to −1.8)P = 0.004
  • Pain scores: nonclinically relevant higher pain scores for opioid anesthesia

Time to first analgesia

Reduced time to first analgesia
88 min (MD, 88 min; 95% CI, 18 to 159; P = 0.01)

Postanesthesia care unit (PACU) length of stay (LOS)

No differences in PACU LOS

Safety

OutcomeRR (95% CI)P value
PONV0.55 (0.40–0.74)P < 0.001

Bradycardia

No significant differences in bradycardia rates

Original publication

Opioid-free anesthesia for minimally invasive abdominal surgery: a systematic review, meta-analysis, and trial sequential analysis. Can J Anaesth. Published 5 November 2024. doi:10.1007/s12630-024-02831-0

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.